Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 1/2013

01-01-2013 | Brief Report

Hepatitis C virus genotype diversity in Shanghai, China

Authors: Shaokun Pan, Yuliang Rao, Jiangyan Li, Huijuan Yang, Jing Tang, Renqian Zhong, Jianwei Zhai, Jing Liu, Hao Wang, Wei Liu, Youhua Xie

Published in: Archives of Virology | Issue 1/2013

Login to get access

Abstract

We studied 67 hepatitis C virus (HCV) isolates from 64 hospitalized patients in Shanghai, China. Genotype 1 was prevalent, and genotypes 2, 3, 6 were found for the first time in Shanghai. A rare mixed infection with three subtypes (1a, 1b, 2a) was found. The complete genome sequence of a subtype 3b isolate was determined and analyzed.
Literature
1.
Chayama K, Tsubota A, Koida I, Arase Y, Saitoh S, Ikeda K, Kumada H (1994) Nucleotide sequence of hepatitis C virus (type 3b) isolated from a Japanese patient with chronic hepatitis C. J Gen Virol 75(Pt 12):3623–3628PubMedCrossRef
2.
Chen YD, Liu MY, Yu WL, Li JQ, Dai Q, Zhou ZQ, Tisminetzky SG (2003) Mix-infections with different genotypes of HCV and with HCV plus other hepatitis viruses in patients with hepatitis C in China. World J Gastroenterol 9:984–992PubMed
3.
Cui XH, Pan W, Qi ZT (1995) Genotyping of hepatitis C virus in patients with hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 75(92–93):126–127
4.
Fu Y, Wang Y, Xia W, Pybus OG, Qin W, Lu L, Nelson K (2011) New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat 18:42–52PubMedCrossRef
5.
Hnatyszyn HJ (2005) Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 10:1–11PubMed
6.
Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, Lai ST, Chang FY (2001) Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 65:505–509PubMedCrossRef
7.
Jiang W, Gu S, Hu Y (1999) Genotyping of HCV isolates from different populations in Shanghai by using second generation line probe assay. Zhonghua Gan Zang Bing Za Zhi 7:29–30PubMed
8.
Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570–574PubMedCrossRef
9.
Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH (2005) Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 75:538–549PubMedCrossRef
10.
Lu L, Nakano T, Li C, Fu Y, Miller S, Kuiken C, Robertson BH, Hagedorn CH (2006) Hepatitis C virus complete genome sequences identified from China representing subtypes 6k and 6n and a novel, as yet unassigned subtype within genotype 6. J Gen Virol 87:629–634PubMedCrossRef
11.
Lu L, Li C, Fu Y, Thaikruea L, Thongswat S, Maneekarn N, Apichartpiyakul C, Hotta H, Okamoto H, Netski D, Pybus OG, Murphy D, Hagedorn CH, Nelson KE (2007) Complete genomes for hepatitis C virus subtypes 6f, 6i, 6j and 6m: viral genetic diversity among Thai blood donors and infected spouses. J Gen Virol 88:1505–1518PubMedCrossRef
12.
Lu L, Murphy D, Li C, Liu S, Xia X, Pham PH, Jin Y, Hagedorn CH, Abe K (2008) Complete genomes of three subtype 6t isolates and analysis of many novel hepatitis C virus variants within genotype 6. J Gen Virol 89:444–452PubMedCrossRef
13.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965PubMedCrossRef
14.
Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S (2007) Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5 ‘ untranslated region sequences. Journal of Clinical Microbiology 45:1102–1112PubMedCrossRef
15.
Pawlotsky JM (2003) Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 59:1–11PubMedCrossRef
16.
Reed KE, Rice CM (2000) Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242:55–84PubMedCrossRef
17.
Sandres-Saune K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J (2003) Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109:187–193PubMedCrossRef
18.
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F (2011) A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 31(Suppl 2):61–80PubMedCrossRef
19.
Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962–973PubMedCrossRef
20.
Xu B, Lu P, Zhu M (2000) Epidemiological aspects of the genotype of hepatitis C virus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 14:148–150PubMed
Metadata
Title
Hepatitis C virus genotype diversity in Shanghai, China
Authors
Shaokun Pan
Yuliang Rao
Jiangyan Li
Huijuan Yang
Jing Tang
Renqian Zhong
Jianwei Zhai
Jing Liu
Hao Wang
Wei Liu
Youhua Xie
Publication date
01-01-2013
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 1/2013
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-012-1457-x

Other articles of this Issue 1/2013

Archives of Virology 1/2013 Go to the issue

Brief Report

Recombinant HCMV UL128 expression and functional identification of PBMC-attracting activity in vitro

Brief Report

Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies

Erratum

Erratum to: Recombinant HCMV UL128 expression and functional identification of PBMC-attracting activity in vitro

Original Article

Pathogen-derived resistance using a viral nucleocapsid gene confers only partial non-durable protection in peanut against peanut bud necrosis virus

Original Article

Epigenetic silencing of WNT5A in Epstein-Barr virus-associated gastric carcinoma

Brief Report

Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits